Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER

CNS Spectrums

Volumn 12, Issue 9, 2007, Pages 703-711

  Stahl, Stephen M ^a,d   Ahmed, Saeeduddin ^b   Haudiquet, Vincent ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

^c Global Biostatistics and Programming   (France)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VENLAFAXINE;

ADULT; ANXIETY; ANXIETY DISORDER; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BEHAVIOR; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; FEAR; FEMALE; GASTROINTESTINAL TRACT; HUMAN; INSOMNIA; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MUSCLE; OPTIMAL DRUG DOSE; POST HOC ANALYSIS; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RESPIRATORY SYSTEM; SOMATIZATION; SOMATOSENSORY CORTEX; SYMPTOMATOLOGY; TENSION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 35348851018     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900021544     Document Type: Article

References (32)

1. Yonkers KA, Warshaw MG, Massion AO, Keller MB. Phenomenology and course of generalised anxiety disorder. Br J Psychiatry. 1996;168:308-313.
2. Grant BF, Hasin DS, Stinson FS, et al. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2005;35:1747-1759.
3. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. text rev. Washington, DC: American Psychiatric Association; 2000.
4. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington. DC: American Psychiatric Association; 1994.
5. Maier W, Gansicke M, Freyberger HJ, Linz M, Heun R, Lecrubier Y. Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: a valid diagnostic entity? Acta Psychiatr Scand. 2000;101:29-36.
6. Yonkers KA, Dyck IR, Warshaw M, Keller MB. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry. 2000;176:544-549.
7. Hoehn-Saric R, McLeod DR, Zimmerli WD. Symptoms and treatment responses of generalized anxiety disorder patients with high versus low levels of cardiovascular complaints. Am J Psychiatry. 1989;146:854-859.
8. Tyrer PJ, Lader MH. Response to propranolol and diazepam in somatic and psychic anxiety. Br Med J. 1974;2:14-16.
9. Rickels K, Weisman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry. 1982;43(12 pt 2):81-86.
10. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of Imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50:884-895.
11. Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2003;160:749-756.
12. Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry. 2004;65:1696-1707.
13. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand. 1997;95:444-550.
14. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62:350-357.
15. Stocchi F, Nordera G, Jokinen RH, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 2003;64:250-258.
16. Ball SG, Kuhn A, Wall D, Shekhar A, Goddard AW. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry. 2005;66:94-99.
17. Allgulander C, Dahl AA, Austin C, et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry. 2004;161:1642-1649.
18. Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety. 2004;19:234-240.
19. Sheehan DV. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. J Clin Psychiatry. 1999;60:23-28.
20. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001;179:15-22.
21. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA. 2000;283:3082-3088.
22. Montgomery SA, Sheehan DV, Meoni P, Haudiquet V, Hackett D. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res. 2002;36:209-217.
23. Pollack MH, Meoni P, Otto MW, Hackett D. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol. 2003;23:250-259.
24. Meoni P, Hackett D, Lader M. Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder. Depress Anxiety. 2004;19:127-132.
25. Kelsey JE. Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder. Depress Anxiety. 2000;12:81-84.
26. Meoni P, Salinas E, Brault Y, Hackett D. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. J Clin Psychiatry. 2001;62:888-893.
27. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CWS Spectr 2005;10:732-747.
28. Lipman R, Covi L. Outpatient treatment of neurotic depression: medication and group psychotherapy. In: Spitzer RL, Klein DL, eds. Evaluation of the Psychological Therapies. Baltimore, Md: Johns Hopkins University Press; 1976;178-218.
29. Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000;157:968-974.
30. Raskin A, Schulterbrandt JG, Reatig N. Rater and patient characteristics associated with rater differences in psychiatric scale ratings. J Clin Psychol. 1966;22:417-423.
31. Mitte K, Noack P, Steil R, Hautzinger M. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol. 2005;25:141-150.
32. Trivedi MH, Rush AJ, Wisniewski SR, etal. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.